Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies ...

Dr. Park shares the three biggest takeaways, in his opinion, to have come out of the ASCO GU Symposium, highlighting studies ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that ...

Prostate cancer affects one in eight men during their lifetime, making it the second most common cancer among American males.

Along with its UC indication, Trodelvy is also FDA-approved for previously treated metastatic triple-negative ... treatment for non-muscle-invasive bladder cancer (NMIBC).

Over the last years, many biological markers emerged that act as an adjunct for the detection of early bladder cancer recurrence. Some of these markers had a proven better sensitivity and ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

The researchers had previously found 15 genes in mice that had an effect on cancer metastasis. They found that mice lacking a gene which produces a protein called ARHGEF1 had less metastasis of ...

I also have 2 tumors in my lung. These are all metastases of my melanoma. Unfortunately, the website also notes, “Metastatic cancer is usually harder to treat than cancer that hasn’t spread.” The ...

HEROES is Natera's first clinical trial using Signatera to guide de-escalation of therapy in patients with metastatic HER2+ breast cancer Approximately 170 patients are expected to enroll in up ...